If you suffered losses exceeding $50,000 in Intellia between July 30, 2024 and January 8, 2025 and would like to discuss your ...

NEW YORK, NY / ACCESS Newswire / March 19, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...

Intellia Therapeutics (NASDAQ:NTLA) traded higher on Thursday as investors cheered pipeline updates the gene-editing biotech delivered with its better-than-expected Q4 2024 results. Cambridge, ...

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD despite promising trials.

Jones Financial Companies Lllp increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by ...

Bank of New York Mellon Corp reduced its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 1.3% in the 4th quarter, according to the company in its most recent 13F ...

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA ...

Analysts are intrested in these 5 stocks: ( ($PLTR) ), ( ($GOLD) ), ( ($INTU) ), ( ($NTLA) ) and ( ($BYON) ). Here is a ...

Using CRISPR/Cas9 gene-editing technology, Intellia Therapeutics develops gene-editing treatments for genetic diseases. The company's lead programs, NTLA-2001 and NTLA-2002, target transthyretin ...

Intellia Therapeutics, Inc. (NTLA) shares rallied 6.5% in the last trading session to close at $12.28. This move can be attributable to notable volume with a higher number of shares being traded ...

Intellia Therapeutics details progress in Phase 3 trials for NTLA-2002 and nex-z, anticipating key regulatory submissions by 2026. Intellia Therapeutics has announced the initiation of the global ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...